Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer

  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Background There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of complement activation fragments. Methods We assessed complement activation in four bronchial epithelial and seven lung cancer cell lines. C4d, a degradation product of complement activation, was determined in 90 primary lung tumors; bronchoalveolar lavage supernatants from patients with lung cancer (n = 50) and nonmalignant respiratory diseases (n = 22); and plasma samples from advanced (n = 50) and early lung cancer patients (n = 84) subjects with inflammatory lung diseases (n = 133), and asymptomatic individuals enrolled in a lung cancer computed tomography screening program (n = 190). Two-sided P values were calculated by Mann-Whitney U test. Results Lung cancer cells activated the classical complement pathway mediated by C1q binding that was inhibited by phosphomonoesters. Survival was decreased in patients with high C4d deposition in tumors (hazard ratio [HR] = 3.06; 95% confidence interval [CI] = 1.18 to 7.91). C4d levels were increased in bronchoalveolar lavage fluid from lung cancer patients compared with patients with nonmalignant respiratory diseases (0.61 +/- 0.87 vs 0.16 +/- 0.11 mu g/mL; P < .001). C4d levels in plasma samples from lung cancer patients at both advanced and early stages were also increased compared with control subjects (4.13 +/- 2.02 vs 1.86 +/- 0.95 mu g/mL, P < 0.001; 3.18 +/- 3.20 vs 1.13 +/- 0.69 mu g/mL, P < .001, respectively). C4d plasma levels were associated with shorter survival in patients at advanced (HR = 1.59; 95% CI = 0.97 to 2.60) and early stages (HR = 5.57; 95% CI = 1.60 to 19.39). Plasma C4d levels were reduced after surgical removal of lung tumors (P < .001) and were associated with increased lung cancer risk in asymptomatic individuals with (n = 32) or without lung cancer (n = 158) (odds ratio = 4.38; 95% CI = 1.61 to 11.93). Conclusions Complement fragment C4d may serve as a biomarker for early diagnosis and prognosis of lung cancer., This work was supported by UTE project CIMA; the Spanish Government (grant numbers ISCIII-RTICC RD06/0020/0066, RD06/0020/1024, RD12/0036/0025, RD12/0036/0040, RD12/0036/0062, PI08/0923, PI10/01652, PI10/00166, and PI11/00618); the European Regional Development Fund; the European Community’s Seventh Framework Programme (HEALTH-F2-2010-258677- CURELUNG); and the Early Detection Research Network from the National Cancer Institute (grant number U01 CA152662). This work was supported (in part) by a grant (RD12/0036/XXXX) from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness & European Regional Development Fund “Una manera de hacer Europa”.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

  • Larrayoz, Marta
  • Pio, Ruben
  • Pajares, María José
  • Zudaire, Isabel
  • Ajona, Daniel
  • Casanovas i Casanovas, Oriol
  • Montuenga, Luis M.
  • Agorreta, Jackeline
The vascular endothelial growth factor (VEGF) pathway is a clinically validated antiangiogenic target for non-small cell lung cancer (NSCLC). However, some contradictory results have been reported on the biological effects of antiangiogenic drugs. In order to evaluate the efficacy of these drugs in NSCLC histological subtypes, we analyzed the anticancer effect of two anti-VEGFR2 therapies (sunitinib and DC101) in chemically induced mouse models and tumorgrafts of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Antiangiogenic treatments induced vascular trimming in both histological subtypes. In ADC tumors, vascular trimming was accompanied by tumor stabilization. In contrast, in SCC tumors, antiangiogenic therapy was associated with disease progression and induction of tumor proliferation. Moreover, in SCC, anti-VEGFR2 therapies increased the expression of stem cell markers such as aldehyde dehydrogenase 1A1, CD133, and CD15, independently of intratumoral hypoxia. In vitro studies with ADC cell lines revealed that antiangiogenic treatments reduced pAKT and pERK signaling and inhibited proliferation, while in SCC-derived cell lines the same treatments increased pAKT and pERK, and induced survival. In conclusion, this study evaluates for the first time the effect of antiangiogenic drugs in lung SCC murine models in vivo and sheds light on the contradictory results of antiangiogenic therapies in NSCLC.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

  • Nogales, Vanesa
  • Reinhold, William C.
  • Varma, Sudhir
  • Martínez Cardús, Anna
  • Moutinho, Cátia
  • Moran, Sebastian
  • Heyn, Holger
  • Sebio, Ana
  • Barnadas i Molins, Agustí
  • Pommier, Yves
  • Esteller, Manel, 1968-
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized as a factor conferring distinct tumoral drug sensitivity, so we have used a comprehensive DNA methylation microarray platform to interrogate the widely characterized NCI60 panel of human cancer cell lines with respect to CpG methylation status and cisplatin/carboplatin sensitivity. Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds. We have also experimentally validated these findings in vitro. In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for the observed chemoresistance effect. Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer

  • Ajona, Daniel
  • Razquin, Cristina
  • Pastor, Maria Dolores
  • Pajares, María José
  • Garcia, Javier
  • Cardenal Alemany, Felipe
  • Fleischhacker, Michael
  • Lozano, Maria Dolores
  • Zulueta, Javier J.
  • Schmidt, Bernd
  • Nadal, Ernest
  • Paz-Ares, Luis
  • Montuenga, Luis M.
  • Pio, Ruben
Molecular markers in bronchial fluids may contribute to the diagnosis of lung cancer. We previously observed a significant increase of C4d-containing complement degradation fragments in bronchoalveolar lavage (BAL) supernatants from lung cancer patients in a cohort of 50 cases and 22 controls (CUN cohort). The present study was designed to determine the diagnostic performance of these complement fragments (hereinafter jointly referred as C4d) in bronchial fluids. C4d levels were determined in BAL supernatants from two independent cohorts: the CU cohort (25 cases and 26 controls) and the HUVR cohort (60 cases and 98 controls). A series of spontaneous sputum samples from 68 patients with lung cancer and 10 controls was also used (LCCCIO cohort). Total protein content, complement C4, complement C5a, and CYFRA 21-1 were also measured in all cohorts. C4d levels were significantly increased in BAL samples from lung cancer patients. The area under the ROC curve was 0.82 (95% CI = 0.71-0.94) and 0.67 (95% CI = 0.58-0.76) for the CU and HUVR cohorts, respectively. In addition, unlike the other markers, C4d levels in BAL samples were highly consistent across the CUN, CU and HUVR cohorts. Interestingly, C4d test markedly increased the sensitivity of bronchoscopy in the two cohorts in which cytological data were available (CUN and HUVR cohorts). Finally, in the LCCCIO cohort, C4d levels were higher in sputum supernatants from patients with lung cancer (area under the ROC curve: 0.7; 95% CI = 0.56-0.83). In conclusion, C4d is consistently elevated in bronchial fluids from lung cancer patients and may be used to improve the diagnosis of the disease.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts

  • Vizoso, Miguel
  • Puig, Marta
  • Carmona, F. Javier
  • Maqueda, Maria
  • Velásquez Vacca, Adriana
  • Gómez, Antonio
  • Labernadie, Anna
  • Lugo, Roberto
  • Gabasa Ferràndez, Marta
  • Rigat Brugarolas, Luis Guillermo
  • Trepat Guixer, Xavier
  • Ramírez Ruz, J. (José)
  • Moran, Sebastian
  • Vidal, Enrique
  • Reguart, Noemí
  • Perera Lluna, Alexandre
  • Esteller, Manel, 1968-
  • Alcaraz Casademunt, Jordi
Epigenetic changes through altered DNA methylation have been implicated in critical aspects of tumor progression, and have been extensively studied in a variety of cancer types. In contrast, our current knowledge of the aberrant genomic DNA methylation in tumor-associated fibroblasts (TAFs) or other stromal cells that act as critical coconspirators of tumor progression is very scarce. To address this gap of knowledge, we conducted genome-wide DNA methylation profiling on lung TAFs and paired control fibroblasts (CFs) from non-small cell lung cancer patients using the HumanMethylation450 microarray. We found widespread DNA hypomethylation concomitant with focal gain of DNA methylation in TAFs compared to CFs. The aberrant DNA methylation landscape of TAFs had a global impact on gene expression and a selective impact on the TGF-β pathway. The latter included promoter hypermethylation-associated SMAD3 silencing, which was associated with hyperresponsiveness to exogenous TGF-β1 in terms of contractility and extracellular matrix deposition. In turn, activation of CFs with exogenous TGF-β1 partially mimicked the epigenetic alterations observed in TAFs, suggesting that TGF-β1 may be necessary but not sufficient to elicit such alterations. Moreover, integrated pathway-enrichment analyses of the DNA methylation alterations revealed that a fraction of TAFs may be bone marrow-derived fibrocytes. Finally, survival analyses using DNA methylation and gene expression datasets identified aberrant DNA methylation on the EDARADD promoter sequence as a prognostic factor in non-small cell lung cancer patients. Our findings shed light on the unique origin and molecular alterations underlying the aberrant phenotype of lung TAFs, and identify a stromal biomarker with potential clinical relevance.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

A prognostic DNA methylation signature for stage I non-small-cell lung cancer

  • Sandoval, Juan
  • Méndez González, Jesús
  • Nadal, Ernest
  • Chen, Guoan
  • Carmona, F. Javier
  • Sayols, Sergi
  • Moran, Sebastian
  • Heyn, Holger
  • Vizoso, Miguel
  • Gómez, Antonio
  • Sánchez Céspedes, Montserrat
  • Assenov, Yassen
  • Müller, Fabian
  • Bock, Christoph
  • Taron, Miquel
  • Mora, Josefina
  • Muscarella, Lucia A.
  • Liloglou, Triantafillos
  • Davies, Michael P. A.
  • Pollán, Marina
  • Pajares, María José
  • Torre, Wenceslao
  • Montuenga, Luis M.
  • Brambilla, Elisabeth
  • Field, John K.
  • Roz, Luca
  • Lo Iacono, Marco
  • Scagliotti, Giorgio V.
  • Rosell Costa, R.
  • Beer, David G.
  • Esteller, Manel, 1968-
Purpose Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard. Patients and Methods A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA methylation markers were validated by a single-methylation pyrosequencing assay in an independent cohort of 143 patients with stage I NSCLC. Results Unsupervised clustering of the 10,000 most variable DNA methylation sites in the discovery cohort identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P = .004). The study in the validation cohort of the significant methylated sites from the discovery cohort found that hypermethylation of five genes was significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished patients with high-and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P = .001). Conclusion The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging. (C) 2013 by American Society of Clinical Oncology.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Comprehensive genomic profiles of small cell lung cancer

  • George, Julie
  • Lim, Jing Shan
  • Jang, Se Jin
  • Cun, Yupeng
  • Ozretić, Luka
  • Kong, Gu
  • Leenders, Frauke
  • Lu, Xin
  • Fernández Cuesta, Lynnette
  • Bosco, Graziella
  • Müller, Christian
  • Dahmen, Ilona
  • Jahchan, Nadine S.
  • Park, Kwon-Sik
  • Yang, Dian
  • Karnezis, Anthony N.
  • Vaka, Dedeepya
  • Torres, Angela
  • Segura Wang, Maia
  • Korbel, Jan O.
  • Menon, Roopika
  • Chun, Sung-Min
  • Kim, Deokhoon
  • Wilkerson, Matt
  • Hayes, Neil
  • Engelmann, David
  • Putzer, Brigitte
  • Bos, Marc
  • Michels, Sebastian
  • Vlasic, Ignacija
  • Seidel, Danila
  • Pinther, Berit
  • Schaub, Philipp
  • Becker, Christian
  • Altmuller, Janine
  • Yokota, Jun
  • Kohno, Takashi
  • Iwakawa, Reika
  • Tsuta, Koji
  • Noguchi, Masayuki
  • Muley, Thomas R.
  • Hoffmann, Hans
  • Schnabel, Philipp A.
  • Petersen, Iver
  • Chen, Yuan
  • Soltermann, Alex
  • Tischler, Verena
  • Choi, Chang-min
  • Kim, Yong-Hee
  • Massion, Pierre P.
  • Zou, Yong
  • Jovanovic, Dragana
  • Kontic, Milica
  • Wright, Gavin M.
  • Russell, Prudence A.
  • Solomon, Benjamin
  • Koch, Ina
  • Lindner, Michael
  • Muscarella, Lucia A.
  • Torre, Annamaria la
  • Field, John K.
  • Jakopovic, Marko
  • Knezevic, Jelena
  • Castanos Vélez, Esmeralda
  • Roz, Luca
  • Pastorino, Ugo
  • Brustugun, Odd-Terje
  • Lund-Iversen, Marius
  • Thunnissen, Erik
  • Köhler, Jens
  • Schuler, Martin
  • Botling, Johan
  • Sandelin, Martin
  • Sánchez Céspedes, Montserrat
  • Salvesen, Helga B.
  • Achter, Viktor
  • Lang, Ulrich
  • Bogus, Magdalena
  • Schneider, Peter M.
  • Zander, Thomas
  • Ansen, Sascha
  • Hallek, Michael
  • Wolf, Jürgen
  • Vingron, Martin
  • Yatabe, Yasushi
  • Travis, William D.
  • Nürnberg, Peter
  • Reinhardt, Christian
  • Perner, Sven
  • Heukamp, Lukas
  • Büttner, Reinhard
  • Haas, Stefan A.
  • Brambilla, Elisabeth
  • Peifer, Martin
  • Sage, Julien
  • Thomas, Roman K.
We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation. Thus, loss of the tumour suppressors TP53 and RB1 is obligatory in SCLC. We discovered somatic genomic rearrangements of TP73 that create an oncogenic version of this gene, TP73Dex2/3. In rare cases, SCLC tumours exhibited kinase gene mutations, providing a possible therapeutic opportunity for individual patients. Finally, we observed inactivating mutations in NOTCH family genes in 25% of human SCLC. Accordingly, activation of Notch signalling in a pre-clinical SCLC mouse model strikingly reduced the number of tumours and extended the survival of the mutant mice. Furthermore, neuroendocrine gene expression was abrogated by Notch activity in SCLC cells. This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis

  • Rodriguez-Paredes, M.
  • Vázquez-Cedeira, Marta
  • Lazo, Pedro A.
  • Esteller, M.
Disruption of the histone modification patterns is one of the most common features of human tumors. However, few genetic alterations in the histone modifier genes have been described in tumorigenesis. Herein we show that the histone methyltransferase SETDB1 undergoes gene amplification in non-small and small lung cancer cell lines and primary tumors. The existence of additional copies of the SETDB1 gene in these transformed cells is associated with higher levels of the corresponding mRNA and protein. From a functional standpoint, the depletion of SETDB1 expression in amplified cells reduces cancer growth in cell culture and nude mice models, whereas its overexpression increases the tumor invasiveness. The increased gene dosage of SETDB1 is also associated with enhanced sensitivity to the growth inhibitory effect mediated by the SETDB1-interfering drug mithramycin. Overall, the findings identify SETDB1 as a bona fide oncogene undergoing gene amplification-associated activation in lung cancer and suggest its potential for new therapeutic strategies., This work was supported by the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant agreement number HEALTH-F2-2010-258677—CURELUNG project, the Institute of Health Carlos III (ISCIII)—PI10/02992, Ministerio de Educación, Ciencia e Innovación Grant SAF2010-14935, Kutxa-Fundación INBIOMED and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis

  • Anadón, C.
  • Guil, S.
  • Simó-Riudalbas, L.
  • Moutinho, C.
  • Setien, F.
  • Martínez-Cardús, A.
  • Moran, S.
  • Villanueva, A.
  • Calaf, M.
  • Vidal, August
  • Lazo, Pedro A.
  • Zondervan, I.
  • Savola, S.
  • Kohno, T.
  • Yokota, J.
  • Pouplana, L. R. de
  • Esteller, M.
The introduction of new therapies against particular genetic mutations in non-small-cell lung cancer is a promising avenue for improving patient survival, but the target population is small. There is a need to discover new potential actionable genetic lesions, to which end, non-conventional cancer pathways, such as RNA editing, are worth exploring. Herein we show that the adenosine-toinosine editing enzyme ADAR1 undergoes gene amplification in non-small cancer cell lines and primary tumors in association with higher levels of the corresponding mRNA and protein. From a growth and invasion standpoint, the depletion of ADAR1 expression in amplified cells reduces their tumorigenic potential in cell culture and mouse models, whereas its overexpression has the opposite effects. From a functional perspective, ADAR1 overexpression enhances the editing frequencies of target transcripts such as NEIL1 and miR-381. In the clinical setting, patients with early-stage lung cancer, but harboring ADAR1 gene amplification, have poor outcomes. Overall, our results indicate a role for ADAR1 as a lung cancer oncogene undergoing gene amplification-associated activation that affects downstream RNA editing patterns and patient prognosis., This work was supported by the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 268626—EPINORC project, the Grant agreement number HEALTH-F2-2010-258677—CURELUNG project, the Spanish Ministry of Economy and Competitiveness (MINECO Projects no. SAF2011-22803, PI13-01339 and SAF2014-55000- R), the Institute of Health Carlos III (ISCIII)—PI10/02992, Ministerio de Educación, Ciencia e Innovación Grant SAF2010-14935, the Cellex Foundation, the National Cancer Center Research and Development Fund (NCC Biobank: 23 A-1) and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) AGAUR—project no. 2009SGR1315 and 2014SGR633., Peer Reviewed
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts

  • Vizoso, Manuel
  • Puig, Marta
  • Carmona, Francisco Javier
  • Maqueda, María
  • Velásquez, Adriana
  • Gómez, Antonio
  • Labernadie, Anna
  • Lugo, Roberto
  • Gabasa, Marta
  • Rigat-Brugarolas, Luis G.
  • Trepat, Xavier
  • Ramírez, Josep
  • Moran, Sebastian
  • Vidal, Enrique
  • Reguart, Noemí
  • Perera Lluna, Alexandre|||0000-0001-6427-851X
  • Esteller, Manel
  • Alcaraz, Jordi
DNA methylation profiling of TAFs reveals global demethylation and a selective impact on the TGF-beta pathway. Moreover, it suggests the fibrocyte origin of a fraction of TAFs, and identifies a novel prognostic biomarker in non-small cell lung cancer.Epigenetic changes through altered DNA methylation have been implicated in critical aspects of tumor progression, and have been extensively studied in a variety of cancer types. In contrast, our current knowledge of the aberrant genomic DNA methylation in tumor-associated fibroblasts (TAFs) or other stromal cells that act as critical coconspirators of tumor progression is very scarce. To address this gap of knowledge, we conducted genome-wide DNA methylation profiling on lung TAFs and paired control fibroblasts (CFs) from non-small cell lung cancer patients using the HumanMethylation450 microarray. We found widespread DNA hypomethylation concomitant with focal gain of DNA methylation in TAFs compared to CFs. The aberrant DNA methylation landscape of TAFs had a global impact on gene expression and a selective impact on the TGF-beta pathway. The latter included promoter hypermethylation-associated SMAD3 silencing, which was associated with hyperresponsiveness to exogenous TGF-beta 1 in terms of contractility and extracellular matrix deposition. In turn, activation of CFs with exogenous TGF-beta 1 partially mimicked the epigenetic alterations observed in TAFs, suggesting that TGF-beta 1 may be necessary but not sufficient to elicit such alterations. Moreover, integrated pathway-enrichment analyses of the DNA methylation alterations revealed that a fraction of TAFs may be bone marrow-derived fibrocytes. Finally, survival analyses using DNA methylation and gene expression datasets identified aberrant DNA methylation on the EDARADD promoter sequence as a prognostic factor in non-small cell lung cancer patients. Our findings shed light on the unique origin and molecular alterations underlying the aberrant phenotype of lung TAFs, and identify a stromal biomarker with potential clinical relevance.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts

  • Vizoso, Miguel
  • Puig, Marta
  • Carmona, F. Javier
  • Maqueda, Maria
  • Velásquez Vacca, Adriana
  • Gómez, Antonio
  • Labernadie, Anna
  • Lugo, Roberto
  • Gabasa Ferràndez, Marta
  • Rigat Brugarolas, Luis Guillermo
  • Trepat Guixer, Xavier
  • Ramírez Ruz, J. (José)
  • Moran, Sebastian
  • Vidal, Enrique
  • Reguart, Noemí
  • Perera Lluna, Alexandre
  • Esteller, Manel
  • Alcaraz Casademunt, Jordi
Epigenetic changes through altered DNA methylation have been implicated in critical aspects of tumor progression, and have been extensively studied in a variety of cancer types. In contrast, our current knowledge of the aberrant genomic DNA methylation in tumor-associated fibroblasts (TAFs) or other stromal cells that act as critical coconspirators of tumor progression is very scarce. To address this gap of knowledge, we conducted genome-wide DNA methylation profiling on lung TAFs and paired control fibroblasts (CFs) from non-small cell lung cancer patients using the HumanMethylation450 microarray. We found widespread DNA hypomethylation concomitant with focal gain of DNA methylation in TAFs compared to CFs. The aberrant DNA methylation landscape of TAFs had a global impact on gene expression and a selective impact on the TGF-β pathway. The latter included promoter hypermethylation-associated SMAD3 silencing, which was associated with hyperresponsiveness to exogenous TGF-β1 in terms of contractility and extracellular matrix deposition. In turn, activation of CFs with exogenous TGF-β1 partially mimicked the epigenetic alterations observed in TAFs, suggesting that TGF-β1 may be necessary but not sufficient to elicit such alterations. Moreover, integrated pathway-enrichment analyses of the DNA methylation alterations revealed that a fraction of TAFs may be bone marrow-derived fibrocytes. Finally, survival analyses using DNA methylation and gene expression datasets identified aberrant DNA methylation on the EDARADD promoter sequence as a prognostic factor in non-small cell lung cancer patients. Our findings shed light on the unique origin and molecular alterations underlying the aberrant phenotype of lung TAFs, and identify a stromal biomarker with potential clinical relevance.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer

  • Ajona, Daniel
  • Razquin, Cristina
  • Pastor, Maria Dolores
  • Pajares, María José
  • Garcia, Javier
  • Cardenal Alemany, Felipe
  • Fleischhacker, Michael
  • Lozano, Maria Dolores
  • Zulueta, Javier J.
  • Schmidt, Bernd
  • Nadal, Ernest
  • Paz-Ares, Luis
  • Montuenga, Luis M.
  • Pio, Ruben
Molecular markers in bronchial fluids may contribute to the diagnosis of lung cancer. We previously observed a significant increase of C4d-containing complement degradation fragments in bronchoalveolar lavage (BAL) supernatants from lung cancer patients in a cohort of 50 cases and 22 controls (CUN cohort). The present study was designed to determine the diagnostic performance of these complement fragments (hereinafter jointly referred as C4d) in bronchial fluids. C4d levels were determined in BAL supernatants from two independent cohorts: the CU cohort (25 cases and 26 controls) and the HUVR cohort (60 cases and 98 controls). A series of spontaneous sputum samples from 68 patients with lung cancer and 10 controls was also used (LCCCIO cohort). Total protein content, complement C4, complement C5a, and CYFRA 21-1 were also measured in all cohorts. C4d levels were significantly increased in BAL samples from lung cancer patients. The area under the ROC curve was 0.82 (95% CI = 0.71-0.94) and 0.67 (95% CI = 0.58-0.76) for the CU and HUVR cohorts, respectively. In addition, unlike the other markers, C4d levels in BAL samples were highly consistent across the CUN, CU and HUVR cohorts. Interestingly, C4d test markedly increased the sensitivity of bronchoscopy in the two cohorts in which cytological data were available (CUN and HUVR cohorts). Finally, in the LCCCIO cohort, C4d levels were higher in sputum supernatants from patients with lung cancer (area under the ROC curve: 0.7; 95% CI = 0.56-0.83). In conclusion, C4d is consistently elevated in bronchial fluids from lung cancer patients and may be used to improve the diagnosis of the disease.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

  • Larrayoz, Marta
  • Pio, Ruben
  • Pajares, María José
  • Zudaire, Isabel
  • Ajona, Daniel
  • Casanovas i Casanovas, Oriol
  • Montuenga, Luis M.
  • Agorreta, Jackeline
The vascular endothelial growth factor (VEGF) pathway is a clinically validated antiangiogenic target for non-small cell lung cancer (NSCLC). However, some contradictory results have been reported on the biological effects of antiangiogenic drugs. In order to evaluate the efficacy of these drugs in NSCLC histological subtypes, we analyzed the anticancer effect of two anti-VEGFR2 therapies (sunitinib and DC101) in chemically induced mouse models and tumorgrafts of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Antiangiogenic treatments induced vascular trimming in both histological subtypes. In ADC tumors, vascular trimming was accompanied by tumor stabilization. In contrast, in SCC tumors, antiangiogenic therapy was associated with disease progression and induction of tumor proliferation. Moreover, in SCC, anti-VEGFR2 therapies increased the expression of stem cell markers such as aldehyde dehydrogenase 1A1, CD133, and CD15, independently of intratumoral hypoxia. In vitro studies with ADC cell lines revealed that antiangiogenic treatments reduced pAKT and pERK signaling and inhibited proliferation, while in SCC-derived cell lines the same treatments increased pAKT and pERK, and induced survival. In conclusion, this study evaluates for the first time the effect of antiangiogenic drugs in lung SCC murine models in vivo and sheds light on the contradictory results of antiangiogenic therapies in NSCLC.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts

  • Vizoso, Manuel
  • Puig, Marta
  • Carmona, Francisco Javier
  • Maqueda, María
  • Velásquez, Adriana
  • Gómez, Antonio
  • Labernadie, Anna
  • Lugo, Roberto
  • Gabasa, Marta
  • Rigat-Brugarolas, Luis G.
  • Trepat, Xavier
  • Ramírez, Josep
  • Moran, Sebastian
  • Vidal, Enrique
  • Reguart, Noemí
  • Perera Lluna, Alexandre
  • Esteller, Manel
  • Alcaraz, Jordi
DNA methylation profiling of TAFs reveals global demethylation and a selective impact on the TGF-beta pathway. Moreover, it suggests the fibrocyte origin of a fraction of TAFs, and identifies a novel prognostic biomarker in non-small cell lung cancer.Epigenetic changes through altered DNA methylation have been implicated in critical aspects of tumor progression, and have been extensively studied in a variety of cancer types. In contrast, our current knowledge of the aberrant genomic DNA methylation in tumor-associated fibroblasts (TAFs) or other stromal cells that act as critical coconspirators of tumor progression is very scarce. To address this gap of knowledge, we conducted genome-wide DNA methylation profiling on lung TAFs and paired control fibroblasts (CFs) from non-small cell lung cancer patients using the HumanMethylation450 microarray. We found widespread DNA hypomethylation concomitant with focal gain of DNA methylation in TAFs compared to CFs. The aberrant DNA methylation landscape of TAFs had a global impact on gene expression and a selective impact on the TGF-beta pathway. The latter included promoter hypermethylation-associated SMAD3 silencing, which was associated with hyperresponsiveness to exogenous TGF-beta 1 in terms of contractility and extracellular matrix deposition. In turn, activation of CFs with exogenous TGF-beta 1 partially mimicked the epigenetic alterations observed in TAFs, suggesting that TGF-beta 1 may be necessary but not sufficient to elicit such alterations. Moreover, integrated pathway-enrichment analyses of the DNA methylation alterations revealed that a fraction of TAFs may be bone marrow-derived fibrocytes. Finally, survival analyses using DNA methylation and gene expression datasets identified aberrant DNA methylation on the EDARADD promoter sequence as a prognostic factor in non-small cell lung cancer patients. Our findings shed light on the unique origin and molecular alterations underlying the aberrant phenotype of lung TAFs, and identify a stromal biomarker with potential clinical relevance., Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Comprehensive genomic profiles of small cell lung cancer

  • George, Julie
  • Lim, Jing Shan
  • Jang, Se Jin
  • Cun, Yupeng
  • Ozretić, Luka
  • Kong, Gu
  • Leenders, Frauke
  • Lu, Xin
  • Fernández Cuesta, Lynnette
  • Bosco, Graziella
  • Müller, Christian
  • Dahmen, Ilona
  • Jahchan, Nadine S.
  • Park, Kwon-Sik
  • Yang, Dian
  • Karnezis, Anthony N.
  • Vaka, Dedeepya
  • Torres, Angela
  • Segura Wang, Maia
  • Korbel, Jan O.
  • Menon, Roopika
  • Chun, Sung-Min
  • Kim, Deokhoon
  • Wilkerson, Matt
  • Hayes, Neil
  • Engelmann, David
  • Putzer, Brigitte
  • Bos, Marc
  • Michels, Sebastian
  • Vlasic, Ignacija
  • Seidel, Danila
  • Pinther, Berit
  • Schaub, Philipp
  • Becker, Christian
  • Altmuller, Janine
  • Yokota, Jun
  • Kohno, Takashi
  • Iwakawa, Reika
  • Tsuta, Koji
  • Noguchi, Masayuki
  • Muley, Thomas R.
  • Hoffmann, Hans
  • Schnabel, Philipp A.
  • Petersen, Iver
  • Chen, Yuan
  • Soltermann, Alex
  • Tischler, Verena
  • Choi, Chang-min
  • Kim, Yong-Hee
  • Massion, Pierre P.
  • Zou, Yong
  • Jovanovic, Dragana
  • Kontic, Milica
  • Wright, Gavin M.
  • Russell, Prudence A.
  • Solomon, Benjamin
  • Koch, Ina
  • Lindner, Michael
  • Muscarella, Lucia A.
  • Torre, Annamaria la
  • Field, John K.
  • Jakopovic, Marko
  • Knezevic, Jelena
  • Castanos Vélez, Esmeralda
  • Roz, Luca
  • Pastorino, Ugo
  • Brustugun, Odd-Terje
  • Lund-Iversen, Marius
  • Thunnissen, Erik
  • Köhler, Jens
  • Schuler, Martin
  • Botling, Johan
  • Sandelin, Martin
  • Sánchez Céspedes, Montserrat
  • Salvesen, Helga B.
  • Achter, Viktor
  • Lang, Ulrich
  • Bogus, Magdalena
  • Schneider, Peter M.
  • Zander, Thomas
  • Ansen, Sascha
  • Hallek, Michael
  • Wolf, Jürgen
  • Vingron, Martin
  • Yatabe, Yasushi
  • Travis, William D.
  • Nürnberg, Peter
  • Reinhardt, Christian
  • Perner, Sven
  • Heukamp, Lukas
  • Büttner, Reinhard
  • Haas, Stefan A.
  • Brambilla, Elisabeth
  • Peifer, Martin
  • Sage, Julien
  • Thomas, Roman K.
We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation. Thus, loss of the tumour suppressors TP53 and RB1 is obligatory in SCLC. We discovered somatic genomic rearrangements of TP73 that create an oncogenic version of this gene, TP73Dex2/3. In rare cases, SCLC tumours exhibited kinase gene mutations, providing a possible therapeutic opportunity for individual patients. Finally, we observed inactivating mutations in NOTCH family genes in 25% of human SCLC. Accordingly, activation of Notch signalling in a pre-clinical SCLC mouse model strikingly reduced the number of tumours and extended the survival of the mutant mice. Furthermore, neuroendocrine gene expression was abrogated by Notch activity in SCLC cells. This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

  • Nogales, Vanesa
  • Reinhold, William C.
  • Varma, Sudhir
  • Martínez Cardús, Anna
  • Moutinho, Cátia
  • Moran, Sebastian
  • Heyn, Holger
  • Sebio, Ana
  • Barnadas i Molins, Agustí
  • Pommier, Yves
  • Esteller, Manel
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized as a factor conferring distinct tumoral drug sensitivity, so we have used a comprehensive DNA methylation microarray platform to interrogate the widely characterized NCI60 panel of human cancer cell lines with respect to CpG methylation status and cisplatin/carboplatin sensitivity. Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds. We have also experimentally validated these findings in vitro. In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for the observed chemoresistance effect. Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A prognostic DNA methylation signature for stage I non-small-cell lung cancer

  • Sandoval, Juan
  • Méndez González, Jesús
  • Nadal, Ernest
  • Chen, Guoan
  • Carmona, F. Javier
  • Sayols, Sergi
  • Moran, Sebastian
  • Heyn, Holger
  • Vizoso, Miguel
  • Gómez, Antonio
  • Sánchez Céspedes, Montserrat
  • Assenov, Yassen
  • Müller, Fabian
  • Bock, Christoph
  • Taron, Miquel
  • Mora, Josefina
  • Muscarella, Lucia A.
  • Liloglou, Triantafillos
  • Davies, Michael P. A.
  • Pollán, Marina
  • Pajares, María José
  • Torre, Wenceslao
  • Montuenga, Luis M.
  • Brambilla, Elisabeth
  • Field, John K.
  • Roz, Luca
  • Lo Iacono, Marco
  • Scagliotti, Giorgio V.
  • Rosell Costa, R.
  • Beer, David G.
  • Esteller, Manel
Purpose Non-small-cell lung cancer (NSCLC) is a tumor in which only small improvements in clinical outcome have been achieved. The issue is critical for stage I patients for whom there are no available biomarkers that indicate which high-risk patients should receive adjuvant chemotherapy. We aimed to find DNA methylation markers that could be helpful in this regard. Patients and Methods A DNA methylation microarray that analyzes 450,000 CpG sites was used to study tumoral DNA obtained from 444 patients with NSCLC that included 237 stage I tumors. The prognostic DNA methylation markers were validated by a single-methylation pyrosequencing assay in an independent cohort of 143 patients with stage I NSCLC. Results Unsupervised clustering of the 10,000 most variable DNA methylation sites in the discovery cohort identified patients with high-risk stage I NSCLC who had shorter relapse-free survival (RFS; hazard ratio [HR], 2.35; 95% CI, 1.29 to 4.28; P = .004). The study in the validation cohort of the significant methylated sites from the discovery cohort found that hypermethylation of five genes was significantly associated with shorter RFS in stage I NSCLC: HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9. A signature based on the number of hypermethylated events distinguished patients with high-and low-risk stage I NSCLC (HR, 3.24; 95% CI, 1.61 to 6.54; P = .001). Conclusion The DNA methylation signature of NSCLC affects the outcome of stage I patients, and it can be practically determined by user-friendly polymerase chain reaction assays. The analysis of the best DNA methylation biomarkers improved prognostic accuracy beyond standard staging. (C) 2013 by American Society of Clinical Oncology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

  • Nogales, Vanesa
  • Reinhold, William C.
  • Varma, Sudhir
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Moutinho, Catia|||0000-0003-3885-0847
  • Moran, S.|||0000-0003-4192-8983
  • Heyn, Holger|||0000-0002-3276-1889
  • Sebio, Ana|||0000-0003-3333-2370
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Pommier, Yves
  • Esteller, M.|||0000-0003-4490-6093
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized as a factor conferring distinct tumoral drug sensitivity, so we have used a comprehensive DNA methylation microarray platform to interrogate the widely characterized NCI60 panel of human cancer cell lines with respect to CpG methylation status and cisplatin/carboplatin sensitivity. Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds. We have also experimentally validated these findings in vitro. In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for the observed chemoresistance effect. Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.